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1. Introduction 
Hormone-regulated and cAMP-mediated 'switch-on' 
of glycogen breakdown in liver or lipolysis in fat cells 
has been extensively studied. In contrast, little is 
known about the hormonal regulation of the 'switch- 
off' mechanism. 
A feedback regulator in the incubation medium of 
fat cells was reported [1], which inhibited adenylate 
cyclase but activated cAMP-dependent protein kinase 
[2]. In [3,4] a second messenger for insulin was 
reported which should be a peptide ofM r ~ 1500. 
In [5,6] the regulatory properties of a second mes- 
senger-type r gulator were described, which inhibits 
adenylate cyclase and protein kinase and activates 
phosphoprotein phosphatase. Because of this counter- 
action to cAMP it was named cAMP antagonist, cAMP 
antagonist appears to be a mediator [7] of hormonally 
controUed switch-off mechanism in liver, muscle, heart 
and brain, since it inhibits the cAMP-dependent pro- 
tein kinases in these tissues [5]. This report describes 
the biosynthesis and purification of cAMP antagonist. 
2. Materials and methods 
Male albino rats (Sprague-Dawley strain; 170-230 g 
body wt; fed ad libitum) were used. After anaesthesia 
with sodium nembutal (30-40 mg/kg body wt) livers 
were excised and hepatocytes were prepared as in [8]. 
Viability of cells as judged by trypan blue exclusion 
was always >80%. Adenylate cyclase activity was mea- 
sured as in [9]. 
2.1. Preparation and purification o f  cAMP an tagonist 
cAMP antagonist was generated by incubating hep- 
atocytes from 1 rat liver at 37°C in 30-50 ml gassed 
(95% 02/5% CO2) Krebs-Ringer bicarbonate buffer 
for 3 5 rain with adrenalin (4.5 X 10 -s M) or insulin 
(5 × 10 -8 M). The cells sedimented by centrifugation 
were resuspended in 30 ml 2.5 mM Tris-HC1 buffer 
(pH 7.5) and homogenized with a Dounce. The 
homogenate was dialyzed 3 times against 150 M 
2.5 mM Tris-HC1 buffer (pH 7.5) within 2 days, and 
after lyophilisation of the dialysis water cAMP antag- 
onist containing raw material was obtained. Material 
from 4-6  rat livers was dissolved in water, poured 
over charcoal (cAMP antagonist does not adsorb), and 
was consecutively chromatographed on Sephadex G- 15 
(using 1.5 X 90 cm column and collecting 2 ml frac- 
tions, cAMP antagonist was eluted in fractions 42-48), 
QAE-Sephadex A-25 (using a 0.9 × 30 cm column 
and collecting 4 ml fractions, cAMP antagonist was 
eluted in fractions 18-20, when a linear gradient of 
150 ml NaC1, 0-400 mM in 50 mM Tris-HC1 buffer 
(pH 7.4) was applied), Sephadex LH-20 (using a 
2.2 X 50 cm column and collecting 2 ml fractions 
cAMP antagonist eluted in fractions 59-64 ahead of 
NaC1, when elution was performed with 60% aqueous 
ethanol) and silicic acid (1.1 X 10 cm column equili- 
brated with benzene/ethylacetate/methanol at 60/40/ 
10, and applying a gradient from 9-100% methanol 
cAMP antagonist was eluted at 50-60% methanol). 
The final step consisted of high-pressure liquid chro- 
matography (HPLC) and was performed on a Nucleosil- 
dimethylamino c lumn (Macherey and Nagel, Dfiren) 
equilibrated with 10 mM Tris-HC1 buffer (pH 7.4); 
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2 ml flow/rain, and developed with a linear gradient 
from 0-500  mM NaC1 on a 30 rain programme run. 
2.2. Assay of cAMP an tagonist 
cAMP antagonist activity was assayed b3): 
(i) Inhibition of  cAMP-dependent protein kinase as 
in [5]; 
(ii) Its ability to inhibit adenylate cyclase. 
Fractions of 10-50 gl containing cAMP antagonist 
were added to 600 gl of  the adenylate cyclase assay 
mixture, when purified plasma membranes were used 
[9]. For measurements of adenylate cyclase activity 
in intact hepatocytes, the assay mixture contained 
5 -10  X 106 hepatocytes, 1 mM theophylline, 20 tzM 
adrenalin and 200 gl of a fraction containing cAMP 
antagonist in a final volume of 1.5 ml gassed Krebs- 
Ringer bicarbonate buffer. Incubations were per- 
formed for 2 min at 37°C. 
At present, the specific activity of cAMP antago- 
nist cannot be given on a molar basis and is therefore 
expressed in units. One unit is defined as the amount 
of  cAMP antagonist, which inhibits protein kinase by 
50% under the experimental conditions described and 
in 0.1 ml reaction volume. 
3. Results 
Stimulation and restimulation of  hepatocytes with 
glucagon each elicited cAMP synthesis. With adrenalin, 
however, no increase of  cAMP synthesis was observed 
after a second stimulation with adrenalin [10], sug- 
gesting that adrenalin stimulation ofhepatocytes leads 
to synthesis of  an intracellular regulator, which inhib- 
its adenylate cyclase. 
3.1. Isolation and purification of cAMP antagonist 
To demonstrate he existence of this hormone-stim- 
ulated regulator, adrenalin-stimulated and non-stimu- 
lated hepatocytes were homogenized (see section 2.1), 
the homogenates were centrifuged at 30 000 X g and 
the supernatants and resuspended sediments were dia- 
lyzed against water. Two adenylate cyclase inhibiting 
activities were present: one activity inform of a sniall 
diffusible molecule, which was more pronounced on 
hormonal stimulation, and the other activity as a non- 
diffusible, membrane-bound component of protein 
nature (it sedimented with the plasma membrane frac- 
tion in a sucrose gradient; it is denatured by heating 
5 min at 80°C or by treatment with 100% ethanol). 
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Fig.1. High-pressure liquid chromatography of cAMP antago- 
nist on N(CH3)~-Nucleosil (10 ~m); flow rate 2 ml/min; linear 
gradient (0-500 mM) NaCI in 10 mM Tris-HC1 buffer 
(pH 7.4) on a 30 min programme run; 1 ml fractions were 
collected and assayed for cAMP antagonist. 
The inhibitory activity present in the supernatant was 
dialysable. This activity, attributed to cAMP antago- 
nist inhibited the cAMP-dependent protein kinase, 
whereas the inhibitory activity of  the purified plasma 
membrane does not inhibit the protein kinase. 
From Sephadex G-15 cAMP antagonist was eluted 
close to ATP, suggesting an app. M r ~ 500. From 
QAE-Sephadex cAMP antagonist was eluted a few 
fractions ahead of cAMP, but much later than prosta- 
glandin E~. Fig.1 shows a high-pressure liquid chro- 
matogram of cAMP antagonist purification. A 3000- 
fold purification was obtained with the first 3 chro- 
matography steps (table 1). 
Nearly equal amounts of cAMP antagonist are 
isolated per rat liver on stimulation with adrenalin 
Table 1 
Scheme for the purification of cAMP antagonist 
mg units units/mg 
Crude extract 4200 n.d. 0.055 
Gel filtration 400 230 0.575 
QAE-Sephadex chromatography 
and desalting on LH-20 10 210 21 
Silicic acid chromatography app. 1 165 165 
Values relate to the material obtained from 10 rat livers; n.d. 
not determined; the units of the crude extract were evaluated 
by assuming that no activity was lost during gel filtration 
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Fig.2. Time course of cAMP antagonist ynthesis n hepato- 
cytes on stimulation with adrenalin (4.5 X 10 -s M) (A) and 
without hormonal stimulation (B). (The shown experiment is 
representative for5 separate expt.) 
(22.5 + 2 units)and insulin (19 + 2 units). No detect- 
able amounts of cAMP antagonist could be isolated 
from hepatocytes without hormonal stimulation. 
(Three separate xperiments were performed, and in 
each experiment material of 10 rat livers was pooled.) 
3 2. Time course ofcAMPantagonist synthesis 
Addition of adrenalin or insulin to hepatocytes 
immediately elicits cAMP antagonist ynthesis, which 
culminates after 3 -5  rain and returns to basal evel 
after 15-20 rain (fig2). When cAMP antagonist yn- 
thesis on adrenalin-stimulation wasperformed in pres- 
ence or absence of adrenergic a- and p-receptor antag- 
onists, results were obtained as shown in table 2. These 
data suggest that on adrenalin-stimulation cAMP antag- 
onist synthesis stimulated via adrenergic a-receptors 
just as cAMP synthesis i stimulated via adrenergic 
p-receptors. 
3.3. Regulatory properties of cAMP antagonist 
Equal amounts of cAMP antagonist per volume 
produce qual percentage of inhibition of both aden- 
ylate cyclase and protein kinase (fig.3). By definition 
10 units of cAMP antagonist/ml assay volume inhibit 
these activities by 50% and 40-50  units/ml assay vol- 
ume lead to 100% inhibition. The basal activity (with- 
out cAMP) and protein kinase fully activated by 
cAMP are inhibited by the same amount of cAMP 
antagonist to an equal extent. Inhibition of cAMP- 
Table 2 
Effects of a- and #-receptor blocking agents on adrenalin- 
stimulated cAMP antagonist ynthesis 
cAMP antagonist isolated on stimu- 
lation with 
cAMP antagonist 
amount obtained 
units % 
(1) Adrenalin 22.2 100 
(2) Adrenalin plus propranolol 21 95 
(3) Adrenalin plus phentolamine 9.9 45 
(4) Control-incubation 
(without adrenalin) 0.9 4 
cAMP antagonist was isolated after 4 min incubation and mea- 
sured after purification by Sephadex G-15 chromatography 
using both adenylate cyclase assays (4.5 X 10 -s M adrenalin; 
10 -s M/3-receptor blocking agent, propranolol; 10 -s M 
a-receptor blocking agent, phentolamine. The shown experi- 
ment is representative for3 separate expt.) 
dependent protein kinase by cAMP antagonist is non- 
competitive with respect o cAMP and ATP. The 
cAMP antagonist inhibits the separated catalytic sub- 
unit (not shown). 
3.4. Role of prostaglandin E in cAMP antagonist yn- 
thesis 
In [11] prostaglandin E (PGE) inhibited adenylate 
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Fig.3. Concentration proffie for the inhibition of adenylate 
cyclase (o - -o )  using plasma membrane assay and of protein 
kinase (A A) by cAMP antagonist; 5,10, 15, 20 and 25 tal 
aliquots of a solution of purified cAMP antagonist were added 
per 0.1 ml assay mixture as in section 2. 
262 
Volume 133, number 2 FEBS LETTERS October 1981 
"-'2. 
n 1.5 3 5 10 
u TINE (min) 
Fig.4. Time course of cAMP antagonist ynthesis nhepato- 
cytes of indomethacin-treated rats: (A) on stimulation with 
adrenalin (4.5 X 10 -2 M);(B) in presence of 1.2 X 10 -6 M 
PGEz, but in absence of adrenalin; (C) in presence of PGE 1 
on stimulation with adrenalin. (The shown experiment is 
representative for3 separate cxpt,) 
cyclase in intact fat cells. Similar effects of PGE can 
be shown in rat liver: by treatment of rats with indo- 
methacin [12] (3-5 doses of 5 mg drug/kg body wt 
within 2 days i.p.) in a dose-dependent manner hepa- 
tocytes from such rats showed increased adrenalin- 
but not glucagon-stimulated cAMP synthesis (from 
43 + 5 pmol to 195 -+ 45 pmol cAMP/5 × 10 6 hepato- 
cytes; calculated from 7 expt). Essentially no cAMP 
antagonist could be isolated from these cells. Impor- 
tantly, upon addition of PGE~ to adrenalin-stimulated 
hepatocytes, cAMP antagonist ynthesis was resumed 
(fig .4). 
tein kinase, activates phosphoprotein phosphatase 
[ 5,7 ] and activates pyruvate dehydrogenase [ 13]. 
These findings suggest that cAMP antagonist is an 
intracellular mediator of the action of a set of differ- 
ent (perhaps anabolic) hormones just as cAMP medi- 
ates the action of a number of different hormones. 
Besides many different possibilities of controlling 
reduction of cAMP synthesis, attention was drawn to 
the fact that inhibition of adenylate cyclase is achieved 
by an adenylate cyclase inhibitor [1]. But the inhibi- 
tor isolated from fat cell media in [1], which activates 
protein kinase [2] is not identical with cAMP antago- 
nist described here. As reported here, there is in addi- 
tion to cAMP antagonist a membrane-bound i hibi- 
tory activity, which inhibits adenylate cyclase. The 
function of this inhibitor is presently unclear. In this 
context it is of interest o note that a cAMP-indepen- 
dent protein kinase activity is present in liver cell 
membranes, which can be activated by cAMP antago- 
nist and which is akeady fully activated when hepato- 
cytes have been stimulated with adrenalin prior to 
membrane isolation ([10], H. K. W. unpublished). It
may be speculated that the adenylate cyclase is inhib- 
ited by cAMP antagonist via phosphorylation by this 
membrane-bound protein kinase after its activation 
by cAMP antagonist. 
The observation [9] that liver plasma membranes 
with an adrenalin-responsive ad nylate cyclase can be 
prepared after inhibition of prostaglandin synthesis 
by indomethacin supports the result in fig.4, suggest- 
ing that PGE is involved in the synthesis of cAMP 
antagonist. PGE1 itself is not the cAMP antagonist, 
since PGE~ neither inhibits adenylate cyclase of plasma 
membranes nor cAMP-dependent protein kinases. As 
will be shown in a following paper (in preparation) 
PGE1 is a component of cAMP antagonist. 
4. Discussion 
The name cAMP antagonist used here for this new, 
intracellular, hormone messenger-like regulator merely 
denotes the fact that this substance acts in an antago- 
nistic fashion to cAMP by inhibiting cAMP-dependent 
protein kinases and activating phosphoprotein phos- 
phatases [5]. After stimulation of hepatocytes with 
insulin a substance can be isolated [7] with properties 
so far indistinguishable from that in adrenalin-stimu- 
lated hepatocytes, in that it behaves identically dur- 
ing chromatographic purification, and it inhibits pro- 
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